Article
This report highlights the VITAL trial; the ORAL Surveillance Study; and the Microbiome study of monozygotic psoriasis patients.
All News
Article
PsA commonly affects peripheral joints. In up to a quarter of PsA patients, the spine may be involved and this is known as psoriatic spondylitis (PsSpA). An important research question is whether PsSpA and Axial Spondyloarthritis (AxSpA) with psoriasis are separate conditions or not.
Olga Petryna
Tweet
Abst0369 #acr2021 @rheumnow #acrbest ⬆️ level of pregnancy complications in axSpA in Irish registry. 41.9% complicated, 11.4% pregnan w/multiple complications. Miscarriage 20.5%. Amongst live births 10.8% c-section, preterm 11.4% . NICU admiss11.4%. ⬇️ breastfeeding rate at 33.7% https://t.co/plF8fykCKT
Olga Petryna
Tweet
Abst0909 #ACR21 @RheumNow #acrbest real life study pinpoints higher disease burden, severity of depressed mood & higher Mean ASAS-HI in F pts w/AS. secukinumab improved disease activity, global functioning and severity of depressive mood in AS patients in both men and women https://t.co/fQycXY1aed
Robert B Chao, MD
Tweet
Great Debate on Voclosporin vs. Belimumab in Lupus Nephritis therapy.
Dr. Petri argues Belimumab has less potential AE including infections, cardiovascular risk, malignancy potential. No drug-drug interactions.
What would you choose?
#ACR21
#ACRBest
@RheumNow https://t.co/FywUp3zCj2
Robert B Chao, MD
Tweet
Differences in secukinumab pain response in AxSpA pts based on HLA-B27 sub-types.
Homozygous group = more uveitis, arthritis, enthesitis, male
Abs#917
#ACR21 @RheumNow
https://t.co/3TL9PdS4xx https://t.co/QQ0Tdye1Z9
sheila
Tweet
EDUCATE! 📣EMPOWER!📣
Prof FMiller shares adaptive measures against predicted impacts of #climate change on rheumatic diseases.
📍We all have a role to play in this.
@RheumNow #ACR21 #MedTwitter #RheumTwitter https://t.co/asJcnm104k
sheila
Tweet
An important slide showing how UV radiation affects #Immunity
🔅suppress APCs
🔅promotes #cytokine production
🔅inhibits cytotoxic & memory T cells
🔅⬆ monocyte recruitment 👉⬆ IFN
🔸⬆UV exposure, ⬆ risk of dev't/flares of #lupus, DM
@RheumNow #ACR21 #climatechange https://t.co/e9glxfy6wR
sheila
Tweet
Interim analysis of AURORA 2 Extension study:
🦋Voclosporin maintained meaningful reductions in UPCR and eGFR remained stable until month 30.
🦋No unexpected new AEs
Promising results!
@RheumNow #ACR21 #ACRBest abs1425 https://t.co/hBB6k0bDYb
Dr. John Cush
Tweet
Identifying Gaps in axSpA: Lessons from European Map of Axial Spondyloarthritis (EMAS)
Dr. Sheila Reyes, ( @RHEUMarampa) discusses the three interesting abstracts were presented by the group of Prof. Marco Garrido-Cumbrera on the EMAS at #ACR21.
https://t.co/Q50kEr5WEU https://t.co/5DScK5krtw
Dr. Rachel Tate
Tweet
CARRA survey in SAID pts reported no change in flare frequency w/ COVID19 but many had reduced intensity of fevers during flares. Majority of pts reported mild to moderate symptoms w/ 1/3 had lingering COVID19 symptoms. Abs 1083 #RheumNow #ACR21 @RheumNow https://t.co/qbfsqvXutt https://t.co/6u33VDIexY
Dr. John Cush
Tweet
AxSpA: Geographic Prevalence Association with HLA-B27: Dr. Rachel Tate ( @uptoTate )
Dr. Rachel Tate discusses abstract #0368 presented at the #ACR21 annual meeting.
https://t.co/CnIjlWuKjZ https://t.co/vytIdK9CCo
Md Yuzaiful Md Yusof
Tweet
#ACR21 #Abstr1457 Nine more well-phenotyped patients with VEXAS were presented. New info:
💠Peritubular capillaritis & cryo vasculitis
💠Most cs- & bDMARDs had limited efficacy
💠Potential therapy with plasma cell blockade & stem cell transplant
@RheumNow https://t.co/iDwJAdbf4M https://t.co/X4ENz4M91u
sheila
Tweet
This post hoc analysis of SPIRIT 1&2 in #psoriaticarthritis pts w/ symptoms indicative of axial involvement showed that Ixekizumab reduced axial symptoms and improved QoL at wks 16 & 24.
Reassuring data.
@RheumNow #ACR21 abs1347 https://t.co/aFixZdiEyx
Dr. John Cush
Tweet
Risankizumab for Active Psoriatic Arthritis with Dr. Robert Chao ( @doctorRBC )
#ACR21
https://t.co/0zskkywWu1 https://t.co/n3qs19rQNG
Janet Pope
Tweet
Interesting results where cannabidiol NEG results in RCT in hand OA and PsA. ? Throw out the ‘pot’with the dish water? Did it stimulate appetites? Was pain the same but interference less? Abst#1456 #ACR21 @RheumNow https://t.co/rnz82Paxkr
David Liew
Tweet
Interesting question came up: why would you change a RA patient from JAKi to JAKi?
The main reason I can think of would be if the first JAKi worked a bit (but not enough to continue, or AEs got in the way).
That would clearly favour to better survival
#ACR21 ABST1442 @RheumNow https://t.co/kDiJVbJfit
Md Yuzaiful Md Yusof
Tweet
#ACR21 #Abstr1484 Hands down one of the most impressive results and trial design. RHAPSODY: Rilonacept led to ⬇️risk of pericarditis recurrence vs PBO (7% vs 74%; HR 0.04). Median time to resolution of pain and CRP were 5 & 7 Days. FDA approved @RheumNow https://t.co/Zty2WnkJEQ https://t.co/xGqt9Lwvjj
Dr. John Cush
Tweet
RheumNow’s expanded coverage of the #ACR21 meeting is sponsored in part by @Novartis. All content chosen by RheumNow & its Faculty.
Md Yuzaiful Md Yusof
Tweet
Realised i have not been out of house apart from hospital visits 😳🙈#MeTime outdoor in the UK 🇬🇧 Falls season while enjoying #ACR21 talks by the New Masters @RheumNow #Rheumpix https://t.co/HYLKkECvCv
